CA-SAMBANOVA-SYSTEMS
SambaNova Systems , the company building the industry’s most advanced software, hardware and services to run AI applications, today announced that its AI membership program for the enterprise, ELEVAITE , is now open for applications. The program is designed to lead select cohorts of enterprises into the AI-enabled future leveraging SambaNova’s unmatched AI technology, solutions, expertise, and proven success while addressing the biggest challenges of starting and scaling an AI program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211026005330/en/
“The emergence of AI and its expected impact on the Global 2000 – akin to the impact of the internet – is upon us,” said Rodrigo Liang, co-founder and CEO of SambaNova. “For those with a desire to embrace the transformational power of AI, there are huge opportunities. With SambaNova ELEVAITE, enterprises will receive unmatched education and technical guidance that directly supports successful AI initiatives from conception to deployment, scalability, and ROI with market visibility for their technology leadership.”
Leaders across industries such as financial services, energy, manufacturing, healthcare, and more realize it is time to apply AI to their organization’s data resources. ELEVAITE is uniquely designed to accelerate selected cohort enterprises’ deployment of the most advanced and performant AI software, hardware, and services available for AI, machine learning, and deep learning.
As an ELEVAITE member, SambaNova teams will work with businesses to determine the most impactful AI technologies based on SambaNova’s experience and deep understanding of enterprise needs to deliver business impact. These include use cases for Natural Language Processing, Vision, and Recommendation.
“Enterprises well suited to participate in ELEVAITE are those that recognize the imperative to drive focus on new initiatives when looking to accelerate AI capabilities inside organizations,” said Marshall Choy, VP of Product at SambaNova. “Working together, ELEVAITE members and SambaNova will accelerate the deployment and scalability inside their enterprises.”
“ELEVAITE membership is designed to deliver unmatched education and awareness on a personal and cohort basis to accelerate enterprises’ transformation to an AI-Enabled organization,” said Amy Love, Chief Marketing Officer at SambaNova. “The program also furthers the market-leading standing of the selected companies by presenting them as leaders in their field.”
ELEVAITE members receive access to three categories of benefits:
- Unmatched Collaboration for Success: By providing customized scoping, implementation and scaling of AI solutions, SambaNova’s dedicated technical and account leads will be with you every step of the way.
- Institutionalized Skills and Knowledge : SambaNova founders, senior executives, board members, technologists, and industry luminaries will educate participating organizations to deliver the resources required to implement AI initiatives and develop new AI skills.
- ELEVAITED Visibility Driving Enterprise Value: With access to the SambaNova VisionAIres program, participants can increase the visibility of their AI initiatives, develop thought leadership and enhance their company’s reputation through media exposure.
ELEVAITE reduces the risk for enterprises and commits to scalable deployment by providing access to unique SambaNova resources and knowledge to ensure they are successful with AI. Members have access to SambaNova’s turnkey platform, including Dataflow-as-a-Service™, an extensible AI services platform, and DataScale®, an integrated software and hardware platform delivering unrivaled performance, accuracy, scale and ease of use built on SambaNova’s Systems Reconfigurable Dataflow Architecture™. This eliminates the need for massive data science staffing, significantly reducing the cost of investment.
To learn more, schedule an executive conversation or to apply for the program, visit sambanova.ai/elevaite . The selection process will occur this fall and the first cohort program will begin in January 2022.
About SambaNova Systems:
SambaNova Systems is an AI innovation company that empowers organizations to deploy best-in-class solutions for natural language processing, computer vision, recommendation systems, and AI for science with confidence. SambaNova's flagship offering, Dataflow-as-a-Service™, helps organizations rapidly deploy AI in days, unlocking new revenue and boosting operational efficiency. SambaNova's DataScale® is an integrated software and hardware system using Reconfigurable Dataflow Architecture™, along with open standards and user interfaces. Headquartered in Palo Alto, California, SambaNova Systems was founded in 2017 by industry luminaries and hardware and software design experts from Sun/Oracle and Stanford University. Investors include SoftBank Vision Fund 2, funds and accounts managed by BlackRock, Intel Capital, GV, Walden International, Temasek, GIC, Redline Capital, Atlantic Bridge Ventures, Celesta, and several others. For more information, please visit us at sambanova.ai or contact us at info@sambanova.ai . Follow SambaNova Systems on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005330/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom